Protein Expression & Purification Services Market Size and Trends
The global protein expression & purification services market reached US$ 4.71 billion in 2025 and is expected to reach US$ 11.81 billion by 2035, growing at a CAGR of 9.6% during the forecast period 2026–2035. The protein expression & purification services market is experiencing robust growth, driven by rising demand for precision medicine, targeted therapies, and immunotherapies that require reliable, scalable protein production. With the increasing focus on developing monoclonal antibodies, recombinant proteins, enzymes, and antibody-drug conjugates (ADCs), biopharmaceutical companies are heavily relying on specialized service providers to accelerate drug discovery and development pipelines. Moreover, advancements in immune checkpoint inhibitors and combination therapies are further boosting the need for high-quality protein expression and purification platforms to ensure efficacy, safety, and regulatory compliance.
Protein Expression & Purification Services Market Scope
| Metrics | Details |
| Market Size (2025) | US$ 4.71 Billion |
| Market Size (2035) | US$ 11.81 Billion |
| CAGR (2026-2035) | 9.60% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | Service Type, Protein Type, Application, End User, Region |
| Leading Region | North America |
| Fastest Growing Region | Asia-Pacific |
Market Size & Forecast
- 2025 Market Size: US$ 4.71 billion
- 2035 Projected Market Size: US$ 11.81 billion
- CAGR (2026–2035): 9.6%
- North America: Largest market in 2025
- Asia Pacific: Fastest-growing market
Protein Expression and Purification Services Market Dynamics
Driver: Rising Demand for Biologics and Therapeutic Proteins
The rising demand for biologics and therapeutic proteins is significantly driving the growth of the protein expression & purification services market. Biologics, including monoclonal antibodies, recombinant proteins, vaccines, and biosimilars, are increasingly used for the treatment of cancer, autoimmune disorders, infectious diseases, and rare genetic conditions. These complex molecules require advanced expression systems and highly precise purification processes to ensure safety, stability, and therapeutic efficacy.
Since establishing in-house infrastructure for large-scale biologic production is costly and technically demanding, many pharmaceutical and biotechnology companies are turning to specialized service providers. The steady increase in the number of biologic approvals, alongside the growing adoption of targeted and personalized therapies, continues to boost demand for reliable protein expression and purification services globally.
Restraint: High Initial Investment and Maintenance Costs
The high cost and complexity of protein expression and purification services pose a major restraint on market growth. Producing recombinant proteins and purifying them to clinical or research-grade standards requires advanced infrastructure, specialized equipment, and highly skilled personnel. The processes often involve multiple expression systems, optimization steps, and sophisticated purification methods such as chromatography, which add to overall expenses. Small biotech firms, academic institutions, and research labs may find these costs prohibitive, limiting their ability to access large-scale or customized services.
Protein Expression & Purification Services Market Segmentation Analysis
The global protein expression & purification services market is segmented by service type, protein type, application, and end-user, and region.
Service Type: The protein purification services segment is estimated to have 58.6% of the protein expression & purification services market share.
Protein purification services currently hold the dominant position in the protein expression & purification services market. This is because purification is a crucial step in ensuring protein quality, stability, and safety for downstream applications such as drug development, diagnostics, and research. Reports indicate that purification accounts for a larger share of the market, contributing to nearly 60% of total revenues. Chromatography-based purification, especially affinity and ion-exchange methods, continues to be widely used due to its effectiveness in producing highly pure proteins. The growing demand for monoclonal antibodies, recombinant proteins, and therapeutic biologics further reinforces the need for advanced purification services, keeping this segment at the forefront.
The protein expression services segment is estimated to have 26.4% of the protein expression & purification services market share.
Protein expression services are emerging as the fastest-growing segment in this market. Outsourcing of protein expression is expanding rapidly, driven by increasing R&D in biologics, vaccines, and precision medicine, where custom recombinant proteins are required in both small and large scales. Pharmaceutical and biotech companies increasingly rely on service providers for efficient, cost-effective, and scalable expression platforms such as mammalian cells, yeast, and cell-free systems. Additionally, rising demand in the Asia-Pacific is accelerating the expansion of this segment. As a result, expression services are expected to register the highest CAGR in the coming years.
Protein Expression and Purification Services Market Geographical Analysis
The North America protein expression & purification services market was valued at 41.6% market share in 2025
North America dominates the protein expression & purification services market, largely due to the region’s well-established pharmaceutical and biotechnology ecosystem, advanced research infrastructure, and high investment in drug discovery and development. The United States, in particular, accounts for the largest share of the market, supported by the presence of leading pharmaceutical companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs) that increasingly outsource protein expression and purification activities. The growing pipeline of biologics, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies, has created sustained demand for high-quality expression and purification services.
Additionally, the regulatory environment in North America is highly supportive of biologics development, with the FDA providing streamlined pathways for approval and commercialization. The strong presence of key market players, coupled with technological advancements in expression systems such as mammalian and cell-free platforms, has reinforced North America’s dominant position. Rising R&D expenditure by both the public and private sectors, along with significant investment in personalized medicine, ensures that the region will continue to lead the global market in the years ahead.
The Europe protein expression & purification services market was valued at 22.8% market share in 2025
Europe maintains a significant position in the protein expression & purification services market, underpinned by its strong biotechnology sector, world-class academic and research institutions, and a well-regulated pharmaceutical landscape. Countries such as Germany, the UK, France, and Switzerland are leading contributors, with a focus on innovation, high-quality biologics development, and advanced protein research. The region is characterized by strong collaborations between academia, biotech firms, and pharmaceutical companies, which have fostered a robust ecosystem for protein-based therapeutics. Europe also places strong emphasis on regulatory compliance and quality standards, which drives demand for specialized purification services that meet stringent requirements for clinical and commercial applications.
Europe’s expertise in biologics manufacturing, its focus on personalized medicine, and its investment in cutting-edge technologies such as next-generation expression systems and high-throughput purification techniques ensure its continued significance. The presence of globally recognized pharmaceutical giants and innovative biotech startups further solidifies Europe’s role as a critical market in the global protein expression and purification services market.
The Asia-Pacific protein expression & purification services market was valued at 19.4% market share in 2025
Asia-Pacific is experiencing the fastest growth in the protein expression & purification services market, fueled by rapid expansion of the biotechnology and pharmaceutical industries across countries such as China, India, Japan, and South Korea. Governments in these nations are heavily investing in life sciences research and infrastructure, while also providing favorable policies to attract foreign pharmaceutical and biotech companies. The rise of contract research and manufacturing organizations (CROs/CDMOs) in the region has made Asia-Pacific an outsourcing hub, offering cost-effective yet high-quality protein expression and purification services.
China and India, in particular, are emerging as hotspots for protein services due to their rapidly growing biotech ecosystems and increasing collaborations with multinational companies. These trends, combined with rising healthcare investments and expanding biopharma manufacturing capabilities, firmly position Asia-Pacific as the fastest-growing regional market.
Protein Expression and Purification Services Market Competitive Landscape
The major players in the protein expression & purification services market include Thermo Fisher Scientific Inc., GenScript, Merck KGaA, Creative Biolabs, Bhat Bio-tech India Private Limited, Charles River Laboratories, Agilent Technologies, Inc., Aragen Life Sciences Ltd., Sino Biological, Inc., Domainex, among others.
Protein Expression and Purification Services Market Key Developments
June 2026: Thermo Fisher Scientific expanded its protein expression and purification service capabilities across North America by introducing advanced mammalian and microbial expression platforms with high-throughput purification workflows, addressing the growing demand for biologics development and accelerating drug discovery timelines.
May 2026: Sartorius AG strengthened its protein production services across Europe by expanding integrated upstream and downstream bioprocessing solutions, enabling biopharmaceutical companies to improve protein yield, scalability, and manufacturing efficiency for therapeutic proteins.
April 2026: GenScript Biotech Corporation enhanced its protein expression and purification service portfolio across the Asia-Pacific region by expanding recombinant protein production capabilities and customized purification technologies, supporting increasing demand for preclinical research, antibody development, and cell and gene therapy applications.
March 2026: Cytiva expanded its protein purification technologies across North America and Europe by introducing advanced chromatography resins and automated purification systems, helping research organizations and biopharmaceutical manufacturers improve process efficiency, product quality, and regulatory compliance.
February 2026: Merck KGaA (MilliporeSigma) strengthened its protein expression and purification services across Europe and Asia-Pacific by expanding contract research and bioprocess development capabilities, driven by rising investments in biologics, biosimilars, and precision medicine, enabling faster therapeutic protein development and commercialization.
Industry Impact Assessment
The increasing shift toward biologics development is reshaping outsourcing strategies throughout pharmaceutical manufacturing. Organizations are prioritizing specialized service providers capable of delivering regulatory-compliant protein production while reducing capital expenditure and shortening development timelines.
At the same time, continued advances in purification technologies, automation, and expression platforms are improving manufacturing efficiency, supporting broader commercialization of recombinant therapeutics and next-generation biologics.
Why This Report Matters
This market report provides strategic intelligence for:
- Pharmaceutical and biotechnology companies evaluating outsourcing strategies.
- CDMOs and CROs expanding protein manufacturing capabilities.
- Investors assessing opportunities within biologics manufacturing.
- Life science technology providers developing protein production platforms.
- Procurement teams identifying qualified service partners.
- Corporate strategy teams monitoring competitive positioning and regional expansion opportunities.
Target Audience
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Development and Manufacturing Organizations (CDMOs)
- Contract Research Organizations (CROs)
- Diagnostic Laboratories
- Clinical Research Centers
- Academic Research Institutions
- Protein Engineering Companies
- Life Science Technology Providers
- Investors and Private Equity Firms
- Government Research Organizations
- Healthcare Strategy and Procurement Teams
Analyst Conclusion
The Protein Expression & Purification Services Market is positioned for sustained expansion as biologics continue to account for an increasing share of pharmaceutical innovation. Rising investment in monoclonal antibodies, recombinant proteins, vaccines, and personalized therapies is creating consistent demand for specialized expression and purification capabilities that many organizations prefer to outsource rather than develop internally.
While infrastructure costs and technical complexity remain important considerations, continued advances in expression technologies, purification platforms, and integrated CDMO services are improving operational efficiency across the value chain. Companies that combine scalable manufacturing capacity, regulatory expertise, advanced purification technologies, and comprehensive biologics development services are expected to strengthen their competitive position through 2035, making this market an important area for strategic investment and long-term business growth.
Suggestions for Related Report
- Breast Cancer Therapeutics Market
- Breast Cancer Treatment Market
- Antibody Drug Conjugates Market
- cell and gene therapy market
For more pharmaceutical-related reports, please click here
